Exploring the therapeutic mechanism of Longqi Fang for diabetic kidney disease based on network pharmacology and verification in rats.
10.12122/j.issn.1673-4254.2022.02.02
- Author:
Lei XING
1
;
Wen Wen XING
2
;
Hong Min GUO
1
Author Information
1. First Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing 210004, China.
2. Department of Geriatrics, Nanjing Gaochun Hospital of Traditional Chinese Medicine, Nanjing 211300, China.
- Publication Type:Journal Article
- Keywords:
Longqi Fang;
animal experiments;
diabetic kidney disease;
network pharmacology;
nuclear factor-κB
- MeSH:
Animals;
Diabetes Mellitus;
Diabetic Nephropathies/metabolism*;
Network Pharmacology;
Phosphatidylinositol 3-Kinases/metabolism*;
Protein Interaction Maps;
Rats;
Rats, Sprague-Dawley
- From:
Journal of Southern Medical University
2022;42(2):171-180
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the therapeutic mechanism of Longqi Fang (LQF) for diabetic kidney disease (DKD) based on GEO database and network pharmacology.
METHODS:LQF and DKD targets were obtained using the databases including GEO, TCMSP, CNKI, ChemDraw, and SwissTarget Prediction, and LQF-DKD intersection targets were obtained with VENNY. String was used for protein-protein interaction (PPI) analysis, and R package for KEGG and GO enrichment analysis. Cytoscape 3.7.2 software Network graphs were constructed. The results of network pharmacology analysis were verified in SD rat models of DKD by daily treatment of the rats with LQF at low (1 g/kg), medium (2 g/kg), and high (2 g/kg) doses, and kidney pathology was observed with HE staining and the changes in renal function were assessed. Western blotting was used to detect the expression levels of NF-κB and p-NF-κB proteins.
RESULTS:We identified 760 main targets of LQF, and obtained 1026 differential genes using GEO database and 61 LQF-DKD intersection targets using Venny database. The core targets obtained through PPI network analysis included Myc, EGF, CASP3, VEGFA, CCL2, SPP1, VCAM1 and ICAM1. Go analysis showed that LQF affects mainly nuclear receptor activity and ligand activated transcription factor activity. KEGG analysis showed that LQF affects inflammatory signaling pathways by interfering with NF-κB, TNF, and PI3K-AKT. In rat models of DKD, treatment with LQF resulted in significant improvements of the renal functions (P < 0.05) and glomerular and tubular structure and arrangement in a dose-dependent manner. Western blotting results showed that LQF dose-dependently downregulated NF-κB and p-NF-κB expressions in the rat models.
CONCLUSION:The therapeutic mechanism of LQF for DKD involves multiple components, targets and signal pathways that mediate an inhibitory effect on NF-κB signaling pathway to protect the renal function.
